{"id":4762,"date":"2025-12-16T15:52:25","date_gmt":"2025-12-16T07:52:25","guid":{"rendered":"https:\/\/credevo.com\/s\/?page_id=4762"},"modified":"2026-01-05T19:11:25","modified_gmt":"2026-01-05T11:11:25","slug":"brivaracetam-bioequivalence-study-protocol","status":"publish","type":"page","link":"https:\/\/credevo.com\/s\/brivaracetam-bioequivalence-study-protocol\/","title":{"rendered":"Brivaracetam Bioequivalence Study Protocol"},"content":{"rendered":"\n
\n

With Brivaracetam generating ~\u20ac600M annually<\/strong>, the February 2026 patent expiry<\/strong> is one of the most important CNS events ahead. Generic products of Brivaracetam that will be launched first are expected to secure 70\u201380%<\/strong> of the market before price erosion begins. This ready-to-use protocol<\/strong> provides a complete, launch-ready pathway, helping you move immediately and secure your place in one of the decade\u2019s highest-value CNS generic opportunities.<\/p>\n<\/blockquote>\n\n\n\n

<\/div>\n\n\n\n
\"Brivaracetam_MoA_Credevo\"<\/figure>
\n

Overview<\/strong>: Brivaracetam (Briviact) is used as an adjunct therapy for the treatment of partial-onset seizures, helping to reduce neuronal hyperexcitability and control seizure activity. The medication offers a rapid onset of action and exhibits linear, dose-proportional pharmacokinetics. It is a third-generation antiepileptic drug that functions as a high-affinity ligand of the synaptic vesicle protein SV2A, thereby modulating neurotransmitter release. A bioequivalence study confirms that generic formulations are equivalent to the reference product in terms of systemic exposure.<\/p>\n\n\n\n

<\/div>\n<\/div><\/div>\n\n\n\n

Download the complete, submission-ready BE protocol with all technical details<\/p>\n\n\n\n

What This Protocol Includes<\/p>\n\n\n\n

\n
\n
    \n
  • Study Synopsis<\/li>\n\n\n\n
  • Study Design Narrative<\/li>\n\n\n\n
  • PK Parameter Definitions (AUC, Cmax<\/sub>, Tmax<\/sub>, t\u00bd)<\/li>\n\n\n\n
  • Safety and AE\/ SAE Reporting<\/li>\n\n\n\n
  • Sampling Time Points<\/li>\n\n\n\n
  • Schedule of Assessments<\/li>\n<\/ul>\n<\/div>\n\n\n\n
    \n
      \n
    • Washout period<\/li>\n\n\n\n
    • Scientific Rationale & Regulatory Justification<\/li>\n\n\n\n
    • Dosing & Administration<\/li>\n\n\n\n
    • Inclusion\/ Exclusion Criteria<\/li>\n\n\n\n
    • Sample Handling <\/li>\n\n\n\n
    • Statistical Considerations<\/li>\n<\/ul>\n<\/div>\n<\/div>\n\n\n